Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Anika Therapeutics (ANIK) Cost of Revenue: 2009-2024

Historic Cost of Revenue for Anika Therapeutics (ANIK) over the last 16 years, with Dec 2024 value amounting to $43.9 million.

  • Anika Therapeutics' Cost of Revenue rose 20.51% to $12.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $51.1 million, marking a year-over-year increase of 134.60%. This contributed to the annual value of $43.9 million for FY2024, which is 14.76% up from last year.
  • Per Anika Therapeutics' latest filing, its Cost of Revenue stood at $43.9 million for FY2024, which was up 14.76% from $38.3 million recorded in FY2023.
  • Anika Therapeutics' Cost of Revenue's 5-year high stood at $64.9 million during FY2021, with a 5-year trough of $38.3 million in FY2023.
  • In the last 3 years, Anika Therapeutics' Cost of Revenue had a median value of $40.6 million in 2022 and averaged $40.9 million.
  • As far as peak fluctuations go, Anika Therapeutics' Cost of Revenue spiked by 113.70% in 2020, and later plummeted by 37.38% in 2022.
  • Anika Therapeutics' Cost of Revenue (Yearly) stood at $61.4 million in 2020, then grew by 5.57% to $64.9 million in 2021, then plummeted by 37.38% to $40.6 million in 2022, then decreased by 5.78% to $38.3 million in 2023, then grew by 14.76% to $43.9 million in 2024.